Zhejiang Hisun Pharmaceutical (600267.SH) Subsidiary Obtains CEP Certificate for Everolimus API

Stock News2025-12-12

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., recently received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for everolimus active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).

The CEP certification demonstrates recognition of the API's quality by the European regulated market, confirming its eligibility to enter the EU and other markets that accept CEP certificates in API form. This achievement is expected to positively impact the company's further expansion into international markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161704324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 16:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161704324","market":"sh","top_or_hot":-1,"title":"Zhejiang Hisun Pharmaceutical (600267.SH) Subsidiary Obtains CEP Certificate for Everolimus API","media":"Stock News","content":"<p>Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., recently received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for everolimus active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).</p>\n<p>The CEP certification demonstrates recognition of the API's quality by the European regulated market, confirming its eligibility to enter the EU and other markets that accept CEP certificates in API form. This achievement is expected to positively impact the company's further expansion into international markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Hisun Pharmaceutical (600267.SH) Subsidiary Obtains CEP Certificate for Everolimus API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Hisun Pharmaceutical (600267.SH) Subsidiary Obtains CEP Certificate for Everolimus API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 16:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., recently received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for everolimus active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).</p>\n<p>The CEP certification demonstrates recognition of the API's quality by the European regulated market, confirming its eligibility to enter the EU and other markets that accept CEP certificates in API form. This achievement is expected to positively impact the company's further expansion into international markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1161704324","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161704324","pubTimestamp":1765529783,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., recently received the Certificate of Suitability to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0188":"融资融券","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"浙江海正药业（600267.SH）子公司获得依维莫司原料药CEP证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":1},"content_text":"Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd., recently received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for everolimus active pharmaceutical ingredient (API) from the European Directorate for the Quality of Medicines & HealthCare (EDQM).\nThe CEP certification demonstrates recognition of the API's quality by the European regulated market, confirming its eligibility to enter the EU and other markets that accept CEP certificates in API form. This achievement is expected to positively impact the company's further expansion into international markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161704324","isCrawlerRequest":true}